Conference on Retroviruses and Opportunistic Infections WASHINGTON STATE CONVENTION CENTER Seattle, Washington March 4-7, 2019

Conference Reports for NATAP


Conference on Retroviruses and Opportunistic Infections Boston USA March 8-11, 2020

	Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20) Clinical Pharmacology at CROI 2020 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (05/19/20) HIV Prevention at CROI 2020 - Written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (05/05/20) ------------------------------ Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP - Mark Mascolini (09/25/20) Comorbidities at CROI - mortality, aging..... - (04/20/20) PrEP at CROI 2020 - (04/20/20) GUT INTEGRITY MARKERS AND ASSOCIATIONS WITH ADIPOSITY IN PEOPLE WITH AND WITHOUT HIV - (06/24/20) Creation of Long - Acting Nanoformulated Tenofovir Prodrugs - (05/21/20) Study Suggests PrEP Access Issue: Disparity in Prior Authorizations Across US Regions - (05/20/20) INFILTRATION OF VRC01 INTO THE CEREBROSPINAL FLUID IN HUMANS IN THE RV397 STUDY - (05/20/20) Tenofovir Diphosphate in Dried Blood Spots Predicts Virologic Failure and Resistance - (05/20/20) REAL-LIFE MANAGEMENT OF DRUG-DRUG INTERACTIONS BETWEEN ANTIRETROVIRALS AND STATINS - (05/20/20) Use of an HIV Prediction Model to Evaluate PrEP Coverage in a Large Healthcare System - (05/19/20) Implementation of On-Demand PrEP in a Large Integrated Healthcare System - (05/19/20) Non-Daily Use of HIV Preexposure Prophylaxis in a Large Online Sample in the U.S. - (05/19/20) Biodegradable Implant for Sustained Delivery of Antiretroviral (ARV) - (05/18/20) Bictegravir/FTC/TAF CSF Diffusion in HIV-Infected Patients with CNS Impairment - (05/18/20) Safety and Tolerability of Once Daily BIC/FTC/TAF for Post-Exposure Prophylaxis - (05/18/20) There is a long Long History of Sexual Transmission of HCV in MSM, Heterosexual Men, Women, IDUs & Reinfection too - (05/18/20) TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20) Effect of Integrase Inhibitors on Weight Gain in Children and Adolescents with HIV - (05/11/20) Fat & HIV was a big part of CROI 2020 - (05/11/20) Body Composition Changes Over The Menopausal Transition In Women With and At Risk For HIV - (05/11/20) TELMISARTAN DECREASES MONOCYTE CX3CR1 EXPRESSION IN TREATED HIV - (05/07/20) Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/07/20) RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON InSTI - (05/07/20) MEASURES OF ADIPOSE TISSUE REDISTRIBUTION AND ATHEROSCLEROTIC CORONARY PLAQUE IN HIV - (05/06/20) Fat/Weight Gain/Aging Faster-mitochondria/Fat Tissue/Genetics/Metabolic Rate-Calorie Intake - (05/06/20) INCREASED INFLAMMATORY CX3CR1+GPR56+CD57+ CD4+ T CELLS IN FAT FROM HIV+ DIABETICS - (05/06/20) FAT GAINS OCCUR AFTER ART WITHOUT CHANGES IN METABOLIC RATE OR CALORIC INTAKE - (05/06/20) Cardiac Events in HIV-infected Patients Who Use Tenofovir-Alafenamide - (05/06/20) CYP2B6 GENOTYPE AND WEIGHT-GAIN DIFFERENCES BETWEEN DOLUTEGRAVIR AND EFAVIRENZ - (05/06/20) Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (05/06/20) ViiV COVID-19 Community Response Fund - May 15 Deadline for Research & Community Organizations - (05/05/20) Kidney Disease Rates in DAD & West Africa at Young Ages: VALIDATION OF THE D:A:D CHRONIC KIDNEY DISEASE (CKD) RISK SCORE IN A LARGE AFRICAN COHORT - (05/05/20) Unexpectedly High Rate of Intolerance for Dolutegravir in Real Life Setting - (05/05/20) Hepatitis, HCV, HBV & Fatty Liver at CROI 2020 - (04/29/20) HIV Stigma Predicts Retention in Care Among US Patients in Care - (04/27/20) Postpartum weight changes in women initiating DTG vs EFV in pregnancy: DolPHIN-2 - (04/27/20) Dolutegravir+3TC - 2 Drug ART at CROI 2020 - (04/27/20) Cardiovascular Risk Profile: A Clinic-Based Sample of Youth Living with HIV in the US - (04/20/20) Low Bone Mineral Density in Older People Living with HIV: the Renal-Bone Axis and ART - (04/20/20) INTACT PROVIRAL DNA LEVELS DECLINE IN PEOPLE WITH HIV ON ANTIRETROVIRAL THERAPY - new intact proviral DNA assay - (04/20/20) THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS (04/13/20) THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS (04/13/20) Trends in Marijuana, Alcohol, and Opioid Use in Pregnant and Postpartum Women with HIV (04/13/20) MK-8504 and MK-8583 (Tenofovir Prodrugs) Single-Dose PK and Antiviral Activity in HIV Infection (04/13/20) INDIVIDUAL AND POPULATION-LEVEL IMPACT OF HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS (04/13/20) LARGE HEPATITIS C TRANSMISSION CLUSTER IDENTIFIED AMONG HIV POSITIVE MSM IN BANGKOK (04/13/20) Barriers To Direct-Acting Antiviral Therapy Among HIV/HCV-Coinfected Adults (04/10/20) COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH ONE OR TWO FULLY ACTIVE AGENTS (04/10/20) HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS........no real difference in blips between arms, non-adherence found to cause blips. (04/10/20) CLINICAL AND LABORATORY OUTCOMES 24 WEEKS AFTER STARTING DTG VERSUS EFV IN ACUTE HIV (04/10/20) NOD2 and TLR8 Agonists Enhance IL-15 Mediated Activation of HIV Expression (04/10/20) SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL (04/10/20) RENAL IMPAIRMENT IN A PREEXPOSURE PROPHYLAXIS IMPLEMENTATION COHORT IN AUSTRALIA (04/10/20) SUSTAINED HIV REMISSION IN THE LONDON PATIENT: THE CASE FOR HIV CURE (04/09/20) PGT121 AND VESATOLIMOD IN CHRONICALLY TREATED SHIV-INFECTED RHESUS MONKEYS (04/09/20) Post-Discharge Outcomes Following Acute Coronary Syndrome in HIV [ Disparities for PLWH ] (04/09/20) HIV-1 Drug Resistance in the DISCOVER Pre-exposure Prophylaxis Trial (04/09/20) COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV-INFECTED RHESUS MONKEYS (04/09/20) PREVALENCE OF RESISTANCE AND LIMITED THERAPEUTIC OPTIONS IN PATIENTS VIREMIC ON ART (04/09/20) Drug Resistance is USA & Europe: 2 studies at CROI 2020 (04/09/20) MK-8591/Islatravir vs ART Resistance / Metabolics (04/09/20) PRO 140 IN VITRO ACTIVITY IN HTE SUBJECTS WITH A 4-CLASS DRUG-RESISTANT HIV-1 VIRUS (04/08/20) CLEARANCE OF HPV ANAL HIGH-GRADE INTRAEPITHELIAL LESIONS WITH LOW-DOSE POMALIDOMIDE (04/08/20) ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES (04/08/20) CROI ART/HIV Drug Studies (04/08/20) BRAIN AGE BASED ON SLEEP ENCEPHALOGRAPHY IS ELEVATED IN HIV+ ADULTS ON ART (04/08/20) Dolutegravir in Malawai (04/08/20) HIV TRANSCRIPTION PROFILE IN BLOOD, GUT, LIVER, AND GENITAL TRACT IN SUPPRESSED WOMEN (04/08/20) Need for optimization of screening methods for anal intraepithelial neoplasia in people living with HIV (04/08/20) High Resolution Anoscopy (HRA) in the Real World: Predictors of Guideline-Based Follow Up at a Large Academic Medical Center (04/08/20) ANAL PRECANCER SCREENING AMONG MSM: WHAT IS THE BEST STRATEGY? (04/08/20) START OR SWITCH OF INTEGRASE INHIBITORS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV (04/08/20) CLINICAL SIGNIFICANCE OF gp120 POLYMORPHISMS, TMR IC50FC AND HIV-1 SUBTYPE IN BRIGHTE (04/08/20) 2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting (04/07/20) INTEGRASE INHIBITOR START OR SWITCH IMPACTS LEARNING IN WOMEN WITH HIV (04/07/20) Anal Cancer Screening: Is it Time for Cytology and High-risk HPV Co-testing? (04/07/20) IN VITRO IMPACT OF TAF ON MITOCHONDRIAL FUNCTION IN IMMUNE CELLS (04/07/20) TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20) TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20) Baseline and Acquired Comorbidities in Patients Initiating ART in the HOPS, 2008-2018 (04/07/20) Race Impact on Dolutegravir-Associated Weight Gain Among Previously ART-Naïve People Living with HIV (04/07/20) MORTALITY AMONG PEOPLE WITH HIV WITH A HISTORY OF INJECTION DRUG USE, NEW YORK CITY, 2008-2017 (04/07/20) Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/06/20) IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (04/06/20) VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS (04/06/20) Dolutegravir+3TC - 2 Drug ART at CROI (04/06/20) Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/04/20) DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ (04/04/20) GREATER INCIDENCE OF DIABETES OVER 10 YEARS AMONG DEPRESSED US VETERANS WITH HIV (04/04/20) Diabetes, Weight Gain, & Integrase Inhibitor Use in North American HIV+ Persons (04/04/20) Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (04/04/20) Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (04/04/20) EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/04/20) EXPLAINING RACIAL DISPARITIES IN VIRAL SUPPRESSION AMONG MSM LIVING WITH HIV (04/04/20) EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA (04/04/20) Long Island has 6,649 cases with both counties combined. (04/04/20) HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT (04/04/20) Clinical Features and Outcomes of Patients Stopping DTG for Neuropsychiatric Symptoms (04/04/20) HPTN 078: HIGH INCIDENCE OF HEPATITIS C VIRUS INFECTIONS AMONG MSM (04/02/20) HEPATITIS C VIRUS INFECTION AND COINFECTION WITH HIV AMONG PWID IN 10 US CITIES (04/02/20) Mobile HCV Screening in At-Risk Urban Population Identifies Significant Fibrosis (04/02/20) HCV REINFECTION AFTER DAA TREATMENT AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO (04/02/20) HCV TRANSMISSION AMONG MSM: EXTERNAL INTRODUCTIONS COULD COMPLICATE MICRO-ELIMINATION (04/02/20) INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20) NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20) HBV New Agents (04/02/20) Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection (04/02/20) EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/01/20) Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI) (04/01/20) Adipocyte Dysfunction Despite Reduced Adipose Inflammation in Diabetics with HIV (04/01/20) Once-daily etravirine/raltegravir (400/800 mg) as maintenance regimen (04/01/20) Losartan does not improve lymphatic tissue fibrosis or T-cell recovery in HIV infection (04/01/20) EFFECTS OF HIV, AGE, AND SEX ON SKELETAL MUSCLE MASS AND DENSITY (04/01/20) EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (03/31/20) EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (03/31/20) IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (03/31/20) Women with HIV Have High Overall Burden and Early Accrual of Non-AIDS Comorbidities (03/31/20) VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS (03/31/20) VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (dolutegravir+bDarunavir) (03/31/20) DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/31/20) Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (03/31/20) Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (03/30/20) EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG INSTI-BASED REGIMENS: DATA FROM REAL-LIFE (03/30/20) SHALL WE DANCE? EXTENDING TANGO'S RESULTS TO CLINICAL PRACTICE (03/30/20) EFFECT OF PAST VIROLOGICAL FAILURE ON DOLUTEGRAVIR + LAMIVUDINE AS MAINTENANCE REGIMEN (03/30/20) VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (03/30/20) LONG-TERM DTG+3TC SWITCH EFFICACY IN PATIENTS WITH ARCHIVED 3TC RESISTANCE (03/30/20) Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/30/20) Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20) Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20) EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/30/20) Modifiable Risk Factors for Kidney and Heart Disease Have Less Impact in HIV+ Than HIV- - Mark Mascolini (03/30/20) SEX, NOT DRUG USE, IS DRIVING HCV RE-INFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY (03/30/20) Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment (03/30/20) Hepatitis C Coinfection and Extrahepatic Cancer Incidence among People with HIV (03/30/20) HCV, Opioid Use, Psych Illness Cluster in Veterans Group--Treatment of Opioid Use Very Low (03/30/20) Increased overall life expectancy but not comorbidity-free years for people with HIV - Mark Mascolini (03/27/20) HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20) PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/27/20) PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/27/20) 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/27/20) Effects of HIV on Myelin Maps (03/27/20) NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV (03/27/20) EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/27/20) RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20) Assessment of Immediate Initiation of Antiretroviral Therapy (ART) in New York City (03/26/20) ASSESSMENT OF IMMEDIATE INITIATION OF ANTIRETROVIAL THERAPY IN NYC (03/26/20) TRENDS AND CHARACTERISTICS OF HIV-1 DRUG RESISTANCE IN THE UNITED STATES (2012-2018) (03/25/20) Retinal Thinning in Well-Controlled HIV-infected Patients (03/23/20) EFFECT OF ANTICHOLINERGIC MEDICATIONS ON BRAIN INTEGRITY IN OLDER HIV-POSITIVE ADULTS (03/23/20) BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20) Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20) Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - Mark Mascolini (03/23/20) VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20) CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (03/23/20) Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/20/20) Much Higher Death Rate After Cancer Diagnosis in People With HIV - Mark Mascolini (03/20/20) HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/20/20) CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY DOSING: WEEK 48 RESULTS FROM THE ATLAS-2M STUDY (03/20/20) CROI ART/HIV Drug Studies (03/20/20) PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/20/20) 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/20/20) PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/20/20) HCV Retreatment, Multiple DAA Failures - Case Study (03/18/20) Real-world effectiveness of Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection (03/18/20) Real-world effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C Virus Infection (03/18/20) Progress and Real-Life Challenges for HCV Elimination in People Living with HIV (03/18/20) CAUSES OF DEATH IN PERSONS WITH AND WITHOUT HCV INFECTION (03/18/20) A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir (03/18/20) Risk of Hepatocellular Carcinoma among Persons Living with HIV and Viral Hepatitis Coinfection in the United States and Canada, 1996-2015 (03/18/20) Six-Week SOF/VEL Inferior to 12 Weeks for Recently Acquired HCV - Mark Mascolini (03/18/20) Liver Cancer Rate Rising Since 1996 in North Americans With HIV - Mark Mascolini (03/18/20) Six-Week SOF/VEL Inferior to 12 Weeks for Recently Acquired HCV - Mark Mascolini (03/18/20) HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20) PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/27/20) PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/27/20) SINGLE-CELL GENOMIC ANALYSIS OF BLOOD AND CSF T CELLS IN HIV+ AND HIV- ADULTS......T Cell Exhaustion in CNS HIV (03/17/20) HIV-1 REPLICATION AT <50 C/ML TO 148 WEEKS FOR SWORD 1 TO 148 WEEKS FOR SWORD-1/SWORD-2 Studies with DTG+RPV (03/17/20) MITOCHONDRIAL DNA, COGNITIVE FUNCTION, AND FRAILTY IN OLDER ADULTS WITH HIV (03/17/20) CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES (03/17/20) BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/17/20) Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/17/20) Less Coronary Intervention, Higher Mortality in HIV+ People With Acute Coronary Syndrome - Mark Mascolini (03/17/20) Starting ART With a PI or an InSTI (Mainly Raltegravir) May Heighten Risk of Diabetes - Mark Mascolini (03/17/20) METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES (03/17/20) Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/17/20) Predicted 10-year risks of diabetes and cardiovascular disease in the ADVANCE trial (03/17/20) Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV (03/17/20) VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/17/20) Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/17/20) BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/16/20) Safety, PK, and Efficacy of Low-Dose B/F/TAF in Children ≥2 Years Old Living With HIV (03/16/20) Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study (03/16/20) Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20) DISCOVER: NO EFFECT OF HORMONES ON F/TAF OR F/TDF PK, EFFICACY & SAFETY IN TRANSWOMEN (03/16/20) IMPLEMENTATION OF MOBILE PrEP, STI, AND HIV PREVENTION SERVICES IN SOUTH FLORIDA (03/16/20) PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20) Cabotegravir + Rilpivirine PK Following Long-Acting HIV Treatment Discontinuation (03/16/20) Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/16/20) ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20) DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20) CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20) FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20) DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/16/20) IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS (03/16/20) Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20) ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 Switch Study TANGO Through Week 48 (03/13/20) INSOMNIA AND RISK OF INCIDENT MYOCARDIAL INFARCTION AMONG PEOPLE LIVING WITH HIV (03/13/20) DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20) Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - Mark Mascolini (03/12/20) Modeling-Supported Islatravir Dose Selection for Phase 3 - (03/12/20) CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/12/20) 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20) RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV - (03/12/20) CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/11/20) NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE - (03/11/20) HCV Prevalence Almost 2% in New Mothers in 2 New York State Regions - Mark Mascolini (03/11/20) NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE - (03/11/20) Falling Cirrhosis and HCV Viremia in Baltimore PWID, Maybe Reflecting DAAs - Mark Mascolini (03/11/20) NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20) HORMONE USE AND HIV ALTER CARDIOVASCULAR BIOMARKER PROFILES IN TRANSGENDER WOMEN - (03/11/20) Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV - Mark Mascolini (03/11/20) DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20) Themed Discussion FAT IN FOCUS - (03/11/20) Pre-ART CD4% and HIV Load Tied to Reservoir Size in Early-Treated Infants - Mark Mascolini (03/11/20) GREATER WEIGHT GAIN AFTER SWITCH TO INSTI-BASED REGIMEN FROM NNRTI VS. PI REGIMENS - (03/11/20) Life Expectancy With HIV Improving--But Added Years Often Not Healthy - Mark Mascolini (03/11/20) Community- Versus Clinic-Based ART Boosts HIV Control in African Study - Mark Mascolini (03/11/20) Low Adherence to Treatment and Follow-up of Anal Cancer Precursor - Mark Mascolini (03/11/20) Doubled Risk of non-HIV Mortality in US People at Risk for HIV - Mark Mascolini (03/11/20) Intact Proviral HIV DNA Drops During Long-Term Suppressive ART - Mark Mascolini (03/11/20) Weekly Islatravir Protects Monkeys Against IV Challenge With SIV - Mark Mascolini (03/11/20) Losartan Does Not Improve Inflammation or Fibrosis Markers in Older People on ART - Mark Mascolini (03/11/20) Pomalidomide Clears Anal Cancer Precursor in High Proportion With or Without HIV - Mark Mascolini (03/11/20) Lower CD4/CD8 Ratio Boosts Cancer Risk in US/Canada HIV Group - Mark Mascolini (03/11/20) F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks - Mark Mascolini (03/11/20) Initial Weight, Low CD4/CD8, Low Activity Drive Weight Gains After InSTI Switch - Mark Mascolini (03/11/20) DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20) WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20) FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20) Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20) ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership - (03/11/20) ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting injectable treatment regimen in adults living with HIV-1 - (03/11/20) Glucose Upsets Tied to Worse Physical Function in Men With or Without HIV - Mark Mascolini (03/11/20) LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20) STRUCTURAL ANALYSES OF A BOUND ANTI-CD4 ADNECTIN INHIBITOR OF HIV-1 [Combinectin GSK3732394] - (03/11/20) Mortality 4-Fold Higher With HIV in Canadian Group--in Sync With Comorbidity Tally - Mark Mascolini (03/11/20) Safety & Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers - (03/11/20) HIV Severity and Incident Heart Failure Among Adults in a Large Healthcare System - (03/11/20) WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20) ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - (03/11/20) New Data on Gilead's Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults - (03/11/20) HIV cure from bench to bedside.....and to community - (03/11/20) Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20) SAFETY & PHARMACOKINETICS OF GS-9722 IN HIV-NEGATIVE PARTICIPANTS AND PEOPLE WITH HIV - (03/09/20) A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (03/09/20) Greater Population-Level Viral Control Tied to Lower HIV Incidence in 4 Large Trials - Mark Mascolini - (03/09/20) Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks. ATLAS-2M study - Mark Mascolini (03/09/20) ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - press release - (03/09/20) Merck Announces New Data from Broad HIV Program at CROI 2020 - (03/02/20)